Validation and application of a blood screening method for SARS-CoV-2 nucleic acid
10.13303/j.cjbt.issn.1004-549x.2022.01.003
- VernacularTitle:新型冠状病毒核酸血液筛查方法的验证及应用
- Author:
Liqin HUANG
1
;
Lilin WANG
1
;
Xin ZHENG
1
;
Linfeng WU
1
;
Xiaoxuan XU
1
;
Tong LI
1
;
Ran LI
1
;
Jinfeng ZENG
1
Author Information
1. Shenzhen Blood Center, Shenzhen 518025, China
- Publication Type:Journal Article
- Keywords:
SARS-CoV-2;
fluorescence quantitative PCR;
performance validation;
blood screening
- From:
Chinese Journal of Blood Transfusion
2022;35(1):10-13
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the performance and clinical application of a high-throughput nucleic acid blood screening detection system for SARS-CoV-2, so as to provide basis and technical means for its application in detection of plasma from recovered COVID-19 patients. 【Methods】 The SARS-CoV-2 nucleic acid was detected by real-time fluorescence quantitative PCR, and the sensitivity, precision, anti-interference and other parameters were evaluated. Blood donor samples collected during COVID-19 epidemic period were screened using the detection system to evaluate its applicability. 【Results】 The detection limits of gene N and ORF 1ab were 3.98 copies/mL and 9.38 copies/mL, respectively. The CV of high and low concentration samples were both less than 5%. Hemoglobin at 500 mg/dL and triglyceride at 3g/dL had little effect on the results. The detection system can effectively prevent carryover, thus avoiding false positive results. The SARS-CoV-2 nucleic acid blood screening was carried out in a total of 39 306 blood samples, and all samples were negative. 【Conclusion】 The established method can meet the needs of SARS-CoV-2 nucleic acid screening therefore ensure the safe application of plasma from recovered COVID-19 patients.
